Back to results
US 2026/0076903 A1Published application
Formulations of anti-interleukin 1 receptor 1 antibodies
AssigneeKiniksa Pharmaceuticals, GmbH
InventorsAjit D'Souza, Jianwen XU
Life of this patent
Estimating the term…
Abstract
The present invention provides, among other things, stable formulations comprising an anti-Interleukin 1 Receptor 1 (IL1R1) antibody at a concentration of between than 50-200 mg/ml, wherein the formulation comprises less than 130 mM arginine and a pH of 4.4-6.5, wherein the amount of HMW species in the formulation increases less than 2% upon storage at 25° C. for at least 4 weeks.
Claims24
A stable formulation comprising an anti-interleukin-1 receptor 1 (IL1R1) antibody,
- wherein the formulation comprises less than 130 mM arginine, a buffer and a pH of 4.4-6.5,
- wherein the anti-IL1R1 antibody comprises a HCDR1 of SEQ ID NO:
- 5 (FHWIA), a HCDR2 of SEQ ID NO:
- 6 (IIHPGASDTRYSPSFQG), a HCDR3 of SEQ ID NO:
- 7 (QRELDYFDY), a LCDR1 of SEQ ID NO:
- 8 (RASQSIGSSLH), a LCDR2 of SEQ ID NO:
- 9 (YASQSFS), and a LCDR3 of SEQ ID NO:
- 10 (HQSSSLPLT), and
- wherein the anti-IL1R1 antibody is present at a concentration of 50-200 mg/ml.
6 more elements
Dependencies are inferred from the claim text.